Sequana Medical NV announced data from its North American pivotal POSEIDON study of the alfapump® demonstrating significantly improved quality of life focused on ascites symptoms and physical functions compared to baseline, which is not seen in refractory ascites patients enrolled contemporaneously in the prospective NACSELD3 (North American Consortium for Study of End-Stage Liver Disease) cohort. The two cohorts were matched for Ascites-Q, age, sex and enrolment MELD-NA, which is a scoring system for assessing the severity of chronic liver disease. These data will be presented as an oral poster presentation on Friday 7th June 2024 at 09.30am CEST at the EASL Congress 2024, Europe?s largest event in this domain, taking place in Milan, Italy.

Matched cohort analysis of 37 patients from each study: This was a comparative analysis in which 37 patients from the North Americal pivotal alfapump study (POSEIDON) were matched 1:1 to patients from the NACSELD3 prospective cirrhosis cohort. For the alfapump cohort, Quality of Life (as evaluated by Ascites-Q and SF-36 (Physical Component Score)) improved significantly at six months compared to baseline, but this benefit was not seen in the NACSELD3 cohort. There was no statistically significant difference in mortality, hospitalisations or liver transplants between the two groups; the hospitalisations in the POSEIDON group were mainly observed in the post-implant period.